American Century Companies Inc. Has $347.23 Million Position in Stryker Corporation $SYK

American Century Companies Inc. lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 877,663 shares of the medical technology company’s stock after purchasing an additional 33,922 shares during the quarter. American Century Companies Inc. owned 0.23% of Stryker worth $347,230,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the 2nd quarter worth $26,000. Sachetta LLC grew its stake in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares in the last quarter. Ridgewood Investments LLC raised its holdings in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new position in shares of Stryker in the first quarter valued at approximately $37,000. Finally, MTM Investment Management LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $38,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $368.35 on Friday. The firm has a market cap of $140.87 billion, a P/E ratio of 48.79, a P/E/G ratio of 2.66 and a beta of 0.94. The business’s 50 day moving average price is $369.38 and its 200 day moving average price is $380.70. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the company earned $2.87 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SYK. Evercore ISI decreased their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Truist Financial upped their price target on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research report on Friday, November 14th. UBS Group set a $408.00 target price on shares of Stryker in a report on Monday, October 13th. Wells Fargo & Company raised their target price on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, Rothschild & Co Redburn started coverage on Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,618 shares of company stock worth $185,577,237 over the last ninety days. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.